Left ventricular hypertrophy (LVH) in hypertension has prognostic significance on cardiovascular mortality and morbidity. Recently, we have shown that n-butylidenephthalide (BP) improves human adipose-derived stem cell (hADSC) engraftment via attenuated reactive oxygen species (ROS) production. This prompted us to investigate whether remote transplantation of BP-pretreated hADSCs confers attenuated LVH at an established phase of hypertension. Male spontaneously hypertensive rats (SHRs) aged 12 weeks were randomly allocated to receive right hamstring injection of vehicle, clinical-grade hADSCs, and BP-preconditioned hADSCs for 8 weeks. As compared with untreated SHRs, naïve hADSCs decreased the ratio of LV weight to tibia, cardiomyocyte cell size, and collagen deposition independent of hemodynamic changes. These changes were accompanied by attenuated myocardial ROS production and increased p-STAT3 levels. Compared with naïve hADSCs, BP-preconditioned hADSCs provided a further decrease of ROS and LVH and an increase of local hADSC engraftment, STAT3 phosphorylation, STAT3 activity, STAT3 nuclear translocation, myocardial IL-10 levels, and the percentage of M2 macrophage infiltration. SIN-1 or S3I-201 reversed the effects of BP-preconditioned ADSCs increase on myocardial IL-10 levels. Furthermore, SIN-1 abolished the phosphorylation of STAT3, whereas superoxide levels were not affected following the inhibition of STAT3. Our results highlighted the feasibility of remote transplantation of hADSCs can be considered as an alternative procedure to reverse cardiac hypertrophy even at an established phase of hypertension. BP-pretreated hADSCs polarize macrophages into M2 immunoregulatory cells more efficiently than naïve hADSCs via ROS/STAT3 pathway.
Introduction
Left ventricular hypertrophy (LVH) is a highly frequent biomarker of cardiac damage in the hypertensive population [1] . LVH secondary to essential hypertension is pathological with stimulus to cardiomyocyte growth also activating fibroblasts leading to an interstitial fibrosis. Clinically, cardiac hypertrophy is associated with increased adverse events, including stroke, ventricular dysfunction, ventricular arrhythmias and sudden death [2] . LVH is a characteristic feature of spontaneously hypertensive rat (SHR). The SHR is the most widely used animal model of human essential hypertension. Reactive oxygen species (ROS) including superoxide have been shown to play an early role in mediating ventricular hypertrophy from the pre-hypertrophic stage of SHR [3, 4] . ROS can be produced in the whole tissue of rats; however, skeletal muscle and heart have been shown to be the main sources of ROS [5] . Given LVH is a powerful predictor of cardiovascular morbidity and mortality [2] , regression of LVH is recognized as a target of antihypertensive therapy.
Accumulating evidence has suggested ROS modulate specific intracellular signaling pathways in cardiac cells thereby promoting cardiomyocyte hypertrophy. It has been reported that signal transducer and activator of transcription (STAT) family proteins, especially STAT3, play critical roles in mechanical stress-induced hypertrophy responses [6] . STAT3 nuclear translocation is redox-dependent [7] . STAT3 has been shown to play a role in cardiac resistance to oxidative stress and inflammation [8] . Very recently, we have shown that ROS can modulate myocardial inflammation by STAT3 translocation [9] . Myocardial inflammation has recently emerged as a pathophysiological process contributing to cardiac hypertrophy in cardiac diseases [10] . Following these initial molecular events, leucocytes infiltrate the myocardium and perpetuate the inflammatory process through secretion of cytokines and pro-fibrotic factors. Genetic disruption of inflammatory cytokines IL-6 [11] and IL-1β [12] exerted protective effects in a murine model of pressure overload, reducing hypertrophy and fibrosis.
Macrophages have been shown to mediate the development of LVH [13] . Macrophage abundance has been shown to increase in the pressure-overloaded heart [14] . Macrophages are fundamental mediators of cardiac remodeling during pressure-overload, and serve as a potential therapeutic target to delay or prevent the transition to heart failure. Macrophage depletion by administering an antibody-mediated neutralization of intercellular adhesion molecule 1 reduced LVH during pressure overload [15] . However, the role of macrophages in the pathogenesis of hypertension and LVH remains controversial. For example, a few studies have suggested that macrophage protects against hypertensive cardiac damage [16] , as macrophage depletion increases blood pressure, and accelerates the development of cardiomyopathy [17] . In view of these conflicting reports, we aimed to determine the role of macrophages in hypertension, LVH, and subsequent cardiac fibrosis. Macrophages can be denoted as M1 and M2 macrophages. M1 macrophages are pro-inflammatory, whereas the M2 macrophages are involved in the resolution of inflammation [18] . The M1 macrophages express inflammatory genes, including iNOS. A defining marker of M2 macrophage function is the secretion of arginase-1 and IL-10 [19] . Macrophage phenotypes have been shown to influence myocardial remodeling [9] . A better understanding of the role of macrophage phenotypes in hypertension and pressure overload may contribute to the development of novel, specific therapies to reduce LVH, fibrosis, and heart failure.
We demonstrated that human adipose-derived stem cells (hADSCs) transplantation is a promising new therapy to attenuate myocardial ROS production [20] . The currently adopted therapy of either delivery through intravenous, intracoronary injection, or local intramyocardial injection of stem cells may not be an ideal method [21] . Instead, intramuscular stem cell delivery to the remote organ of interest may be an alternative method for clinical applications. Previous studies have shown that stem cells administered intramuscularly, were still detectable at the implant site more than 100 days after transplantation where they continued to secrete a functional antibody into circulation [22] . Furthermore, Braid et al. [23] have recently shown that intramuscular implantation of stem cells potentiates dwell time far exceeding that of intravenous, intraperitoneal or subcutaneous routes. However, whether the prolonged survival of stem cells by extracardiac intramuscular route can provide better cardioprotection remained unknown. Excessive ROS production in the skeletal muscle was related cardiac hypertrophy [24, 25] . Previous studies showed that local injection of anabolic androgenic steroids as prooxidants [26] in the skeletal muscle resulted in cardiac hypertrophy, which can be reversed by co-administering antioxidants [24, 25] , implying the possible role of locally-produced ROS in mediating cardiac hypertrophy. Thus, it is interesting to assess whether ADSCs transplanted into the extracardiac organs regulate cardiac hypertrophy via a ROS-dependent pathway.
n-Butylidenephthalide (BP) is the major component of Angelica sinensis [27] . Angelica sinensis, a traditional Chinese herbal medicine, has been shown to have a broad spectrum of biological activities, such as anti-inflammatory and anti-oxidative effects [28] . Compared with ADSCs alone, BP pretreatment has been shown to further attenuate ROS production in infarcted myocardium [20] . Thus, we hypothesized that extracardiac transplantation of hADSCs could protect the heart against hypertension-induced ventricular hypertrophy, and that BP-preconditioned hADSCs prior to remote transplantation might enhance the effect. In this study, we assessed 1) whether in vivo extracardiac transplantation of hADSCs results in attenuated myocardial hypertrophy through regulation of macrophage phenotypes, 2) whether the antihypertrophic effect of BP-pretreated hADSCs is superior to naïve hADSCs, and 3) whether the role of superoxide and STAT3 is involved in cardiac hypertrophy by pharmacological intervention in SHR.
Methods
The cell culture and animal experiment were approved and conducted in accordance with local institutional guidelines for the care and use of laboratory animals at the China Medical University (permission number: 2018-043) and conformed with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Isolation of hADSCs
hADSCs were purchased from the commercially available kits (Stempro human ADSC kit; Invitrogen, Carlsbad, CA, U.S.A) and were generously provided by Gwo Xi Stem Cell Applied Technology (Hsinchu, Taiwan) as previously described [20] . In brief, hADSCs were cultured in growth media (Low glucose DMEM (Invitrogen) media, 10% FBS (Serana), and 1% Penicillin/Streptomycin (Hyclone)) and were subcultured using TrypLE Express (Invitrogen) to subsequent passages. Passaged cultures were deemed passage 1. hADSCs at passages 3-5 were used in this study. These hADSCs were homogeneous and did not contain endothelial cells or hematopoietic lineages. Cultured hADSCs have been shown to display mesenchymal stem cell phenotype: they express the mesenchymal stem cell marker CD90 and do not express hematopoietic markers CD31 and CD45. They were confirmed to be > 95% CD90 + and < 2% CD31 + /CD45 + .
Cell transplantation
Two experimental series of male SHR (12 weeks old, an established hypertrophic phase) were prepared for evaluation of attenuated hypertrophic effect of hADSCs in cell transplantation studies.
In the first series, the effect of naïve versus BP-pretreated hADSCs was evaluated in vivo. At 12 weeks of age, male SHR were randomly allocated to one of 3 groups and treated for 8 weeks: (a) vehicle group, which received 30 μl of PBS by intramuscular injection; (b) naïve hADSC group, which were intramuscularly injected in 30 μl of PBS (1 × 10 6 cells); and (c) BP-pretreated hADSC group, which were intramuscularly injected with the same number of BP-pretreated hADSCs in 30 μl of PBS. hADSCs were primed with 7 μg/ml BP (Alfa Aesar) for 16 h before transplantation. Cells were injected into the right hamstrings. Given the 2nd remote injection was found to be unnecessary [29] , only single intramuscular injection was used in this study. Normotensive male Wistar-Kyoto (WKY) rats of the same age served as controls. The hamstring muscle was excised at day 3 and the heart at days 3 and 56 after cell implantation. To exclude an influence of circulating immune cells on the analysis of intracardiac macrophages, we perfused the circulation of the rats with PBS prior to explanting the hearts.
In the second series, although results of the above study showed that BP significantly increased M2 phenotype (see Results), the involved mechanism remained unclear. [30, 31] . Thus, together, the experimental groups studied were: hADSC, BP/hADSC, BP/hADSC/SIN-1, and BP/hADSC/ S3I-201. At the end of the study, all hearts (n = 5 each group) were used for measuring ROS levels, STAT3 activity and IL-10 levels.
Hemodynamics
At 56 days after cell transplantation, hemodynamic parameters were measured in conscious rats. Arterial blood pressure was measured in restrained rats using a tailcuff system (BP-98A, Softron Beijing, Bejing, China) in a dark temperature-controlled room (22°C) in the morning. After the arterial pressure measurement, echocardiogram was performed.
Echocardiogram
Echocardiographic parameters were measured in anesthetized rats with intraperitoneal injection of Zoletil (50 mg/kg) after the arterial pressure measurement as shown in the Supplementary material online.
After this, the atria and the right ventricle were trimmed off, and the LV was rinsed in cold physiological saline, weighed, and immediately frozen in liquid nitrogen.
Western blot analysis of STAT3
Samples were obtained from the LV free wall. Antibodies to phospho (Tyr705)-STAT3 (Cell Signaling Technology, Danvers, MA, USA), total STAT3 (Santa Cruz Biotechnology), and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA) were used. Western blotting procedures were described previously [20] . Experiments were replicated three times and results expressed as the mean value.
Real-time RT-PCR of human Alu, IL-6, IL-1β, iNOS, CD206, IL-10, and BNP
Real-time quantitative RT-PCR was performed from the LV muscle with the TaqMan system (Prism 7700 Sequence Detection System, PE Biosystems) as previously described [20] . We analyzed the expression of gene markers for M1 (IL-6, IL-1β, iNOS) and M2 (CD206, IL-10) macrophages. Primers sequences were the following:Human Alu sense 5′-CATGGTGAAACCCCGTCTCTA-3′, antisense 5′-GCCTCAGCCTCCCG AGTAG-3'; IL-6 sense 5′-CCAGTTGCCTTCTTGGGACTGATG-3′, antisense 5′-ATTTTCTGACCACAGTGAGGAATG-3'; IL-1β sense 5′-ATGGCA ACTGTCCCTGAACTCAACT-3′, antisense 5′-CAGGACAGGTATAGATTC AACCCCTT-3'; iNOS sense 5′-TCACCTTCGAGGGCAGCCGA-3′, antisense 5′-TCCGTGGCAAAGCGAGCCAG-3'; CD206 sense 5′-TGGGTTTG CTGAAGAAGAGAA-3′, antisense 5′-CATGTGATAAGTGACAAATGC TTG-3'; IL-10 sense 5′-GGTTGCCAAGCCTTGTCAGAA-3′, antisense 5′-GCTCCACTGCCTTGCTTTTATT-3'; cyclophilin sense 5′-ATGGTCAAC CCCACCGTGTTCTTCG-3′, antisense 5′-CGTGTGAAGTCACCACCCTGA CACA-3'. Besides, a molecular hallmark of hypertrophy is the reactivation of a set of fetal cardiac genes including BNP in the adult heart [32] . To confirm the gene expression of cardiac hypertrophy, we also performed real-time quantitative RT-PCR of BNP. For BNP, the primers were 5′-AGAGAGCAGGACACCATC-3′, and 5′-AAGCAGGAGCAGAATC ATC-3'. Standard curves were plotted with the threshold cycles versus log template quantities. Fold change was normalized against cyclophilin, a housekeeping gene.
Immunohistochemical analysis of human mitochondria, DHE, Nitrotyrosine, CD68, iNOS, and IL-10
Samples from the hamstring muscles and myocardium at day 3 after implantation were obtained to identify hADSCs in the skeletal muscle and heart and to determine if they engrafted into tissues. We performed immunohistochemistry specific for human mitochondria (Chemicon International) according to the manufacturer's instructions.
To evaluate myocardial intracellular superoxide production, we used in situ dihydroethidium (DHE; Invitrogen Molecular Probes, Eugene, OR, USA) fluorescence. OCT-embedded tissues were incubated with DHE from the hamstring muscles and myocardium as we previously described [33] . DHE fluorescence was digitally recorded using an Olympus microscope. To minimize interference by nonspecific DHE oxidation products, a red fluorescence was detected with excitation line 405 nm [34] . The fluorescence intensity of nuclei from each section was measured and was corrected for background fluorescence in nonnuclear regions with Image-Pro Plus software (Media Cybernetics, Silver Spring, USA). Four sections per rat were studied. The value was expressed as the ratio of labeled fluorescence area to total area. The slides were coded so that the investigator was blinded to the rat identification. At day 56 after implantation, to confirm the shift of macrophage polarization, immunohistochemical staining was performed on LV muscle for M1 and M2 analysis. Cryosections were incubated with antibodies against CD68 (a marker for all macrophages; Abcam, Cambridge, MA), iNOS (a marker for M1; Cell Signaling Technology, Danvers, MA, USA), and IL-10 (a marker for M2c; R& D systems, Abingdon, UK). The antibody had been tested for specificity in the rat. Isotype-identical directly conjugated antibodies served as a negative control. Ten random scans per section were analyzed and averaged. Quantification was calculated as the percentage of positively stained area to total area at a magnification of 400 × .
Morphometry of myocyte size and cardiac fibrosis
Heart sections from the middle part of the LV were stained with hematoxylin-eosin to assess myocyte size and with Sirius red stain to measure interstitial fibrosis. For detailed methods, please refer to Supplementary Methods.
Laboratory measurements
Histologic collagen results were confirmed by hydroxyproline assay adapted from Stegemann and Stalder [35] . The samples from the LV free wall were immediately placed in liquid nitrogen and stored at −80°C until measurement of the hydroxyproline content. The results were calculated as hydroxyproline content per weight of tissue.
To evaluate the DNA-binding activity of STAT3, myocardial homogenates were prepared and a TransAM STAT3 Transcription Factor Assay Kit (Active Motif) was used according to the manufacturer's protocol.
Myocardial IL-10 activity was assayed for M2c. Myocardial tissues from the LV free wall were homogenized in extraction buffer (50 mM potassium phosphate buffer, pH 7.0; 1 mM EDTA; 1 mM ethylene glycol tetraacetic acid; 0.2 mM phenylmethanesulfonylfluoride; 1 μg/mL pepstatin; 0.5 μg/mL leupeptin; 10 mM NaF; 2 mM Na 3 VO 4 ; and 10 mM β-mercaptoethanol), and centrifuged for 30 min at 14,000 g at 4°C. Myocardial membrane-bound IL-10 fractions were measured using commercially available ELISA kits (R&D Systems).
Superoxide production from myocardium was measured using lucigenin (5 μM bis-N-methylacridinium nitrate, Sigma, St. Louis, MO) enhanced chemiluminescence as previously described [36] . The plasma superoxide level was determined using nitro blue tetrazolium reaction in TRIS-buffer [37] . This reaction is specific for superoxide radicals, since the reduction can be inhibited by superoxide dismutase [38] . The measurement was performed at a wavelength of 530 nm.
Statistical analysis
Results were presented as mean ± SD. Statistical analysis was performed using the SPSS statistical package (SPSS, version 19.0, Chicago, Illinois). Differences among the groups of rats were tested by an ANOVA. In case of a significant effect, the measurements between the groups were compared with Bonferroni's correction. The significant level was assumed at value of P < 0.05.
Results

Characterization of hADSCs
Flow cytometry analysis showed that hADSCs were highly positive for CD73, CD90 and CD105. These cells did not express CD14, CD19, CD34, CD45 and HLA-DR. Taken together, the phenotype of the hADSCs in our culture conditions was CD73pos/CD90pos/CD105pos/ CD14neg/CD19neg/CD34neg/CD45neg/HLA-DRneg. These hADSCs were homogeneous and did not contain endothelial cells or hematopoietic lineages. Treatment of hADSCs with BP for 16 h prior to transplantation did not lead to significant changes in cell markers. Superoxide production, as assessed by lucigenin-enhanced chemiluminescence, was markedly increased at the right hamstring muscles in the SHR as compared with WKY (P < 0.01, Fig. 1A) . Superoxide was significantly decreased in hADSC-treated rats compared with vehicle. Furthermore, the extent of attenuated superoxide was significantly higher in the BP/hADSC-treated SHR compared with that in the naïve hADSC-treated SHR. The results of lucigenin-enhanced chemiluminescence were further confirmed by DHE staining (Fig. 1B) .
Myocardial superoxide in untreated SHR significantly increased as compared to WKY (P < 0.01, Fig. 1C ) by lucigenin-enhanced chemiluminescence. Myocardial superoxide in hADSC-treated SHR can be significantly reduced compared with untreated SHR. Similarly, the intensity of DHE staining was attenuated after adding hADSCs and the attenuated extent in BP/hADSC-treated SHR was significantly higher than that in the naïve hADSC-treated SHR (Fig. 1D) .
To confirm the systemic effect of local hADSC transplantation on circulating ROS levels, we performed plasma superoxide measurements. Plasma superoxide levels in hADSC-treated SHR were significantly reduced compared with untreated SHR (10.1 ± 0.32 vs. 11.4 ± 0.72 nmol/ml in untreated SHR, P < 0.05, Fig. 1E ).
Effect of hADSCs on the engraftment at the hamstring muscles and myocardium.
To quantify the survival of transplanted hADSCs, the human origin of these transplanted cells was re-confirmed by staining with anti-human mitochondria antibody 3 days after transplantation (Fig. 1F) . Human stem cells were observed at implanted area of transplantation group. The mitochondria-positive cells were more frequently observed in the rats administered BP. The ratio of mitochondria-positive cells in the BP/hADSCs group was 15.4 ± 5.6%, significantly higher than that in the naïve hADSCs group (7.6 ± 1.3%, P < 0.05). These data suggest that BP administration increases the survival of hADSCs in local injected muscles.
The cells did not migrate detectably from the injection site to myocardium up to 3 days after transplantation assessed by staining with anti-human mitochondria antibody (data not shown). However, as in vivo immunohistochemistry may not be sensitive enough for the detection of a small number of cells, myocardiums were collected for Alu gene analysis by RT-PCR (Fig. 1G) . No amplification was found in the heart. Together, these data strongly indicated that remotely transplanted hADSCs did not migrate significantly into the heart from the injection site.
Part 2: chronic stage at the myocardium (day 56)
hADSC administration did not modify the increase of body weight with age. The SHR groups had similar body weights at baseline (data not shown) and at the end of the study (Table 1) . Untreated SHR showed LV hypertrophy, with a significant increase of 69% in the ratio of LV weight to tibia compared with WKY. Compared with untreated SHR, naïve hADSCs and BP/hADSCs decreased LV weight-to-tibia length ratios by 11.6% and 16.7%, respectively (both P < 0.05). During the 8-wk study period, hemodynamic parameters including blood pressure and heart rate were similar among the SHR groups treated with or without hADSCs. These data indicate the nonhemodynamic effect of hADSCs on ventricular hypertrophy. Besides, there was no local infection or inflammation around the injection site.
Effect of remote hADSC transplantation on cardiac ROS and STAT3 activation.
Myocardial superoxide production, as assessed by lucigenin-enhanced chemiluminescence, was markedly decreased in hADSC-treated SHR as compared with vehicle (P < 0.001, Fig. 2A ). Superoxide levels were significantly decreased in BP/hADSC rats compared with those in naïve hADSC rats.
As shown in Fig. 2B , the myocardium in the untreated SHR markedly enhanced the intensity of the DHE staining compared with WKY. The intensity of the fluorescent signal in the naïve hADSC group was significantly reduced relative to the untreated ADSC group, which was further decreased in the BP/hADSC group.
Then, we examined the downstream molecule of free radicals, STAT3, by Western blot (Fig. 3A) . Phosphorylation of STAT3 (p-tyr705) is significantly decreased in the untreated SHR compared with WKY (P < 0.05). Treatment with hADSCs increased STAT3 activation to 156 ± 21% of untreated SHR (P < 0.01). When compared with naïve hADSC-treated SHR, BP/hADSC-treated SHR had significantly higher STAT3 activation (2.45 ± 0.14 vs. 2.19 ± 0.19, P < 0.05).
Similarly, the DNA-binding activity of STAT3 was significantly increased hADSC-treated SHR, as assessed by transcription factor ELISA (Fig. 3B) .
To evaluate the activation of myocardial STAT3, immune-staining analyses with anti-p(tyr 705)-STAT3 antibody were performed (Fig. 3C) . As a result, myocardial p-STAT3 was localized in the nucleus. The extent of STAT3 nuclear translocation was significantly increased in BP/hADSC-treated SHR than that in the untreated-and naïve hADSCtreated SHR. 
Effect of remote hADSC transplantation on cardiac macrophages skewing toward a M2 phenotype.
To explore the interactions of hADSCs and host macrophages in the myocardium, we characterized the effect of hADSCs on macrophage differentiation by examining type-specific surface marker. To identify the subtype of infiltrated macrophages in the myocardium, the marker for M1 (CD68 + , iNOS + ) and M2c
(CD68 + , IL-10 + ) was examined (Fig. 4) . Compared with WKY, immunohistochemical staining demonstrated that a significant increase of CD68 + macrophages was infiltrated in untreated SHR.
Compared with untreated SHR, iNOS-expressing CD68 + macrophages were significantly decreased in the naïve hADSCs (12 ± 4% in the untreated versus 4 ± 2% in the hADSCs, P < 0.05, Fig. 4A ), and IL-10-expressing CD68 + macrophages were more frequent in the hADSCs (5 ± 3% in the untreated versus 16 ± 5% in the hADSCs, P < 0.05, Fig. 4B ).
To further confirm the macrophage phenotype shift, we performed RT-PCR. M1 mRNA (IL-6, IL-1β, iNOS) was remarkably decreased and M2 mRNA (CD206, IL-10) was highly induced in the SHR treated with naïve and BP-pretreated hADSCs (Fig. 5) . Significantly, BP-primed hADSCs decreased the percentage of M1 macrophages and increased the percentage of M2 macrophages compared with naïve hADSCs. These data suggest improved ability of BP-primed hADSCs-treated rats to increase M2 macrophage differentiation with a concomitant reduction in M1.
Effect of remote hADSC transplantation on cardiac hypertrophy and fibrosis.
To characterize the cardiac hypertrophy on a cellular level, morphometric analyses of LV sections were performed on different treatment groups (Fig. 6A ). Myocytes were significantly hypertrophied in the untreated SHR group compared with those in the WKY (478 ± 32 μm 2 ). hADSCs reduced cell areas by 13% compared with the untreated SHR (P < 0.05). BP-primed hADSCs further reduced cell areas compared with naïve hADSCs. Myocardial expression of BNP, a marker of pathological cardiac hypertrophy, was measured by competitive RT-PCR (Fig. 6B) . BNP was markedly increased in the untreated SHR compared with WKY (2.73-fold, P < 0.0001). Naïve hADSCs reduced BNP expression, consistent with the histological findings. BP-primed hADSCs suppressed the upregulation of BNP to a greater extent than naïve hADSCs.
Fibrosis of the LV was examined in tissue sections after Sirius red staining, as shown in Fig. 6C . SHR treated with hADSCs had significantly smaller areas of intense focal fibrosis compared with vehicle (0.76 ± 0.09% vs. 0.53 ± 0.08%, P < 0.05). The SHR showed further attenuated cardiac fibrosis after administering BP-primed hADSCs. The extent of fibrotic tissue assessed by hydroxyproline amount showed similar results as those from Sirius red staining (Fig. 6D). 
Echocardiography.
In comparison with WKY, untreated SHR hearts showed structural changes such as increased interventricular septal dimension and LV posterior wall dimension (Table 1) , consistent with LV hypertrophy. It is possible that the combination of attenuated hypertrophy and similar hypertension in hADSC-treated SHR vs. untreated SHR might lead to increased wall stress and cardiac dysfunction. However, there was no echocardiographic evidence for LV dysfunction as fractional shortening were similar among the SHR groups. LV diastolic dimension and LV systolic dimension were also similar in naïve hADSC-treated SHR vs. untreated SHR (Table 1) .
Experiment 2. Ex vivo study
The role of ROS/STAT3 signaling in mediating macrophage transformation
To elucidate the role of the superoxide signaling in BP-primed hADSC-induced macrophage polarization, SIN-1 was assessed in an ex vivo model. Fig. 7 shows that SIN-1 significantly decreased levels of p-STAT3 and IL-10 compared with BP/hADSCs alone.
To assess whether the STAT3 signaling pathway is essential for the polarization of M2c macrophages, we examined the effect of S3I-201 on macrophage transformation into M2c. IL-10 activity levels were significantly decreased (P < 0.05) in the BP/hADSCs treated with S3I-201 compared with BP/hADSCs alone (Fig. 7C) . SIN-1 abolished the phosphorylation of STAT3, whereas superoxide levels were not affected following the inhibition of STAT3. Thus, ROS were the upstream to modulate the STAT3 activity.
Discussion
Our results showed for the first time that a therapeutic mechanism of extracardiac hADSC-induced cardiac hypertrophy regression through engagement of the skeletal ROS and cardiac ROS-STAT3 axis at the established stage of hypertension. The potency of BP-primed hADSCs appears to be greater than that treated with naïve hADSCs in terms of attenuated superoxide production, increased STAT3 activity, and In a rat isolated heart model, effect of superoxide and STAT3 on IL-10 levels. STAT3 activity was determined by Western blot analysis using the phospho-STAT3 antibody. SIN-1 significantly decreased STAT3 activity and IL-10 levels compared with BP/hADSCs alone. Besides, the administration of S3I-201, a STAT3 inhibitor, significantly decreased IL-10 levels compared with BP/hADSCs alone. *P < 0.05 versus naïve hADSC; †P < 0.05 versus BP/hADSC-treated group; ‡P < 0.05 versus BP/hADSC/SIN-treated group. Fig. 8 . Proposed schematic representation illustrates the involvement of remotely transplanted hADSCs in macrophage polarization-mediated cardiac hypertrophy. It is characterized by inflammatory M1 phenotype macrophages in untreated SHR, however, after administering hADSCs, M2 phenotype would become dominant in which BP-primed hADSCs further attenuate ROS production and increased STAT3 activity. M1 and M2 phenotype macrophages can be converted into each other. Inhibition of these signaling pathways is indicated by the vertical lines. reduced M1 macrophage infiltration. These observations underscore the central role of macrophage phenotypes in LVH and support a role of trophic factors derived from the remotely injected hADSCs for regenerative therapies to preserve the myocardium in hypertension. Our results were consistent with the beneficial effects of BP-primed hADSCs, as documented structurally by DHE staining, STAT3 nuclear translocation, M1 and M2 infiltration, echocardiographically-derived cardiac function, and cardiac fibrosis, molecularly by myocardial STAT3 protein levels and mRNA for M1 and M2 markers, biochemically by STAT3 DNA binding activity, IL-10 levels, and tissue hydroxyproline levels, and pharmacologically by modulators of superoxide and STAT3. Our results were consistent with the results of Eirin et al. [39] , showing that intrarenal delivery of mesenchymal stem cells attenuates renovascular hypertension-induced myocardial injury.
The novel findings reported here are summarized as follows: (a) remotely transplanted hADSCs survived at the site of injection, with no detectable migration within 3 days after transplantation; (b) despite sustained hypertension, a single extracardiac injection of hADSCs in SHR attenuated myocardial hypertrophy and interstitial fibrosis eight weeks later; (c) remote transplantation of hADSCs induced myocardial changes in their gene expression profile, which may contribute to their cardioprotective effects; and (d) ROS/STAT3/macrophage polarization is possibly the axis evoking cardioprotection after hADSC remote transplantation. Our conclusions are supported by 3 lines of evidence (Fig. 8). 1) Remotely transplanted hADSCs did not migrate to the heart. In our study, cell transplantation did not induce severe local inflammation and cells retained the human mitochondria marker expression at the hamstring muscles 3 days after transplantation, suggesting that they were not significantly differentiated or modified by local environment and their properties were maintained in vivo. This suggests that intramuscular administration is an alternative to conventional routes to achieve sustained benefit from stem cell therapies. We further found that the survival of local stem cells was significantly increased in the group pretreated with BP compared with naïve hADSCs. Furthermore, hADSC migration to the heart was undetectable after the intramuscular injection. Our results were consistent with the findings of Shabbir et al. [40] , showing that intramuscularly injected mesenchymal stem cells are trapped in the muscular bed with no detectable migration to other tissues. However, this does not exclude the possibility that transplanted cells may generate other cell types (parenchymal or stromal cells) or migrate to other places, at later times after transplantation. 2) hADSCs mediated extracardiac ROS and cardiac ROS-STAT3 signaling. hADSCs may produce and release local signaling molecules that limit local inflammation when injected into hamstring muscles. The entrapment of hADSCs within the hamstrings did attenuate superoxide production in the skeletal muscle which was consistent with the findings of Pinheiro et al. [41] , showing that ADSC transplantation into the skeletal muscle was associated with a decrease in local oxidative stress. In addition to local anti-oxidant effect, the plasma superoxide levels were significantly declined by the local hADSC transplantation. Stem cells can secrete extracellular vesicles, including microvesicles (0.1-1 mm in diameter) and exosomes (40-100 nm in diameter), which can be carried to distant targets, attenuate systemic ROS production, and may contribute to the therapeutic potency of stem cells [42] .
The local transplantation of hADSCs reduced myocardial superoxide production at the acute stage. The role of myocardial superoxide involved in the therapeutic mechanisms mediating myocardial STAT3 activity was confirmed by administering SIN-1. STAT3 DNA binding and transcriptional activity is directly regulated by redox status [43] . SIN-1 administration significantly increased myocardial superoxide levels and abolished the phosphorylation of STAT3 compared with BP/ hADSCs alone (Fig. 7A and B) . In contrast, myocardial superoxide levels were not affected following the inhibition of STAT3 compared with BP/ hADSCs alone, implying that ROS were the upstream to modulate the STAT3 activity. Furthermore, either SIN-1 or 3SI-201 reversed the effects of BP-preconditioned ADSCs increase on myocardial IL-10 levels (Fig. 7C) , a marker for M2c macrophage. The results showed the role of STAT3 in regulating macrophage polarization. Our results illustrate a therapeutically relevant trophic factor signaling cascade initiated by hADSCs, which stimulate the cardiac trophic factor network through ROS-STAT3 signaling. Our results were consistent with the findings of Roddy et al. [44] , showing that systemic administration of human mesenchymal stem cells in a mouse model of chemically injured cornea reduced corneal inflammation without engraftment at the site of lesions, by producing and secreting antiinflammatory protein.
We showed that STAT3 activity is similar in untreated SHR compared with WKY, which contrasted with previous study [45] , showing that STAT3 was significantly increased in myocardium of the 22-weekold SHR relative to those obtained from the age-matched normotensive strain WKY. The discrepancy can be explained at least in part by different study design and animal age. STAT3 was selectively activated by in vivo injection of exogenous angiotensin II peptide, different from our in vivo design. Besides, given ROS levels were significantly increased in SHR, STAT3 activity was expected to be reduced in SHR if ROS were the only upstream to modulate the STAT3 activity. Indeed, a number of proteins have been reported to associate with STAT3 and regulate its activity. These STAT3-interacting proteins function to modulate STAT3-mediated signaling at various steps and mediate the crosstalk of STAT3 with other cellular signaling pathways [46] . Thus, it is not surprising to know that the STAT3 activity is not significantly increased in SHR, a model of high ROS.
3) hADSCs attenuated ventricular hypertrophy by regulating macrophage transformation. The heart contains a heterogeneous population of macrophages that are present in both healthy and injured cardiac tissue [47] . Inflammatory activation is considered a central component of cardiac remodeling in response to pressureoverload [48] . Prior work has established that cardiac macrophages in normal and healthy mice resemble an M2-like phenotype [49] , which is typically associated with anti-inflammatory properties. Our findings of greater accumulation of M1 macrophages during pressure-overload suggest a switch to a pro-inflammatory M1 macrophage phenotype that can propagate tissue damage. Our results were consistent with previous findings, showing that macrophage accumulation and the increased expression of mRNA and protein of inflammatory markers were significantly elevated in SHR [50] .
Other mechanisms
Although the present study suggests that the mechanisms of BPprimed hADSC's attenuation of cardiac hypertrophy may be related to increased STAT3-dependent M2 phenotype, other potential mechanisms need to be studied, such as the crosstalk between mesenchymal stem cells and bone marrow endogenous progenitor cells. Shabbir et al. [29] showed that mesenchymal stem cells administered into the hind limb skeletal muscle improved ventricular function in a hamster heart failure model. The authors suggested the crosstalk between mesenchymal stem cells and bone marrow endogenous progenitor cells as being the main mechanism for subsequent increase in myocardial c-kit 1 cells involved in cardiac repair. However, the migration ability of transplanted cells onto the heart was not addressed. Experimental studies have shown that an increase in preload results in the mobilization of progenitor cells from the bone marrow and migration into the heart, which plays an important role in cardiac hypertrophy [51] . Thus, we can not exclude the possibility of stem cells from the bone marrow in modulating ventricular hypertrophy. Here, we demonstrated that remotely transplanted hADSCs at distant sites from the heart expressed paracrine/endocrine factors with cardioprotective effects.
Clinical implications
First, the study suggests that in contrast to the effects observed with small molecule inhibitors targeting hypertophic pathways, a single extracardiac injection of hADSCs appears capable of providing durable alterations in inflammatory cytokine balance and attenuates LVH at the established stage. Besides, the studies were carried out in SHR because the SHR may be considered to be more clinically relevant to the human experience where uncontrolled hypertension leads to cardiac hypertrophy. A delayed treatment to reverse the progression of LVH more closely resembles the situation usually encountered in patients with hypertension. Second, the study suggested that the intramuscular route presents a minimally invasive alternative to conventional intravenous infusion for applications beyond local limb injury. To mimic a more clinical scenario, we determined the therapeutic efficacy of transplanting hADSCs remotely into the hamstring muscles. Long-term secretion of beneficial factors from transplanted cells would possibly provide a sustained effect. Our study suggests that stem cell transplantation at distant sites from the heart allows the engraftment and proliferation of cells at the site of implantation, and thus may become a more effective and less invasive strategy as compared to direct intracardiac delivery of stem cells for myocardial protection. This noninvasive stem cell administration regimen, if validated clinically, is expected to facilitate future stem cell therapy for patients with cardiac hypertrophy. The work will advance our mechanistic understanding of cell-mediated cardioprotection and regeneration, while constituting an important first step towards the development of hADSC-derived exosomes as a novel cell-free therapeutic agent.
Study limitations
There are some limitations in the present study that have to be acknowledged. First, our study was limited by the use of relatively young animals, hypertension duration was shorter, and lack of comorbidities than observed in patients. In clinical trials, comorbidities are far more present in the general population than was anticipated before, making our proposal notable from a translational perspective. Second, previous reports have raised safety concerns about tumors, malformation, or microinfarctions after mesenchymal stem cell therapy [52] . In the current study, no structural changes (tumor or abnormal growth formations) were detected in the lung, liver, spleen, or kidneys (data not shown) by visual inspection ex vivo 8 weeks after cell injection. Previous studies have shown that transplanted mesenchymal stem cells do not form teratomas for up to 17 months after subcutaneous transplantation [53] . Nevertheless, additional long-term follow-up studies are needed to determine the safety of MSC therapy, as well as the optimal dose of cell delivery.
Conclusions
Remote transplantation of hADSCs can be considered as a safe and less invasive procedure to attenuate LVH. These data provide new evidence that the preferential shift of the macrophage phenotype from M1 to M2 may be related to hADSC-related activation of the STAT3 pathway that contributes to attenuated cardiac hypertrophy. The research reported here provides new insight regarding the pathogenesis of LVH and provides a foundation for future clinical trials of stem cell therapy to treat ventricular hypertrophy.
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